ANTIFUNGAL RESISTANCE OF CANDIDA SP. CAUSING VAGINITIS DURING PREGNANCY

Quốc Kỳ Duyên

doi:10.34238/tnu-jst.10930

ANTIFUNGAL RESISTANCE OF CANDIDA SP. CAUSING VAGINITIS DURING PREGNANCY

About this article

Received: 13/08/24 Revised: 17/11/24 Published: 18/11/24

Authors

Quoc Ky Duyen , Nguyen Tat Thanh University

Abstract

Vulvovaginal Candidiasis is a common endogenous fungal infection, ranking second among the causes of vaginitis in women of reproductive age. The infection rate is particularly higher during pregnancy, with 30% of cases compared to 20% in non-pregnant women. This study aimed to determine the antifungal resistance rates of Candida species causing vaginitis during pregnancy. To achieve study goal, we analyzed 88 clinical specimens that tested positive for Candida species from the vaginal discharge of pregnant women diagnosed with vaginitis. The samples were cultured and isolated on sabouraud chloramphenicol agar, then identified using chrome agar Candida, combined with real-time PCR techniques to determine the infection rate of Candida albicans. Results showed that among the 88 clinical specimens, Candida albicans accounted for 53.41% (n = 47), non-albicans Candida species included Candida glabrata (37.5%; n = 33), Candida tropicalis (2.17%; n = 2), Candida krusei (1.14%; n = 1), and other Candida species (5.68%; n = 5). The antifungal resistance of Candida species was assessed using the disc diffusion method, revealing resistance rates of 92.05% for fluconazole, 86.36% for itraconazole, 39.77% for miconazole, 25% for clotrimazole, and 100% sensitivity to nystatin.

Keywords

Vaginitis; Candida sp.; Pregnant women; Antifungal drugs; Candida albicans

Full Text:

PDF (Tiếng Việt)

References

[1] J. D. Sobel, “Vaginitis,” N Engl J Med., vol. 337, no. 26, pp. 1896-1903, 1997, doi: 10.1056/NEJM199712253372607.

[2] T. J. Aguin and J. D. Sobel, “Vulvovaginal candidiasis in pregnancy,” Curr Infect Dis Rep., vol. 17, no. 6, 2015, doi: 10.1007/S11908-015-0462-0.

[3] J. Intra, M. R. Sala, P. Brambilla, D. Carcione, and V. Leoni, “Prevalence and
species distribution of microorganisms isolated among non-pregnant women
affected by vulvovaginal candidiasis: A retrospective study over a 20 yearperiod,” J Mycol Med., vol. 32, no. 3, 2022, doi: 10.1016/J.MYCMED.2022.101278.

[4] F. Mutua, G. Revathi, and J. M. Machoki, “Species distribution and antifungal sensitivity patterns of vaginal yeasts,” East Afr Med J., vol. 87, no. 4, pp. 156-62, 2010, doi: 10.4314/eamj.v87i4.62202.

[5] A. Farr, H. Kiss, I. Holzer, P. Husslein, M. Hagmann, and L. Petricevic, “Effect of asymptomatic vaginal colonization with Candida albicans on pregnancy outcome,” Acta Obstet Gynecol Scand, vol. 94, no. 9, pp. 989-996, 2015.

[6] Z. Dong, C. Fan, W. Hou et al., “Vaginal Exposure to Candida albicans During Early Gestation Results in Adverse Pregnancy Outcomes via Inhibiting Placental Development,” Front Microbiol, vol. 12, 2022, doi: 10.3389/FMICB.2021.816161/FULL.

[7] T. M. C. Ngo and N. P. A. Ton, “Dentification and antifungal resistance of Candida sp. Isolated from patients with vulvovaginal candidoses in Hue university hospital,” Journal of Obstetrics and Gynecology, vol. 13, pp. 44-47, 2016.

[8] N. A. Do et al., “Prevalence of vulvovaginal candidiasis and antifungal susceptibility testing of candida albicans among women in childbearing age in Hanoi (2019 - 2020),” Journal of Military Pharmaco- medicine, vol. 4, pp. 32-39, 2021.

[9] M. Yücesoy and S. Marol, “Performance of Chrome agar Candida and BIGGY agar for identification of yeast species,” Ann Clin Microbiol Antimicrob., vol. 2, no. 1, pp. 1-7, 2003, doi: 10.1186/1476-0711-2-8/TABLES/3.

[10] Clinical and Laboratory Standards Institute (CLSI), Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts, Approved Guideline, vol. 29, 2009.

[11] A. Bitew and Y. Abebaw, “Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern,” BMC Womens Health, vol. 18, no. 1, 2018, doi: 10.1186/S12905-018-0607-Z.

[12] A. Tsega and F. Mekonnen, “Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre80 Markos Referral Hospital, Northwest Ethiopia,” BMC Pregnancy Childbirth, vol. 19, no. 1, 2019, doi: 10.1186/S12884-019-2494-1.

[13] H. P. R. Martins, M. C. da Silva, L. C. F. Paiva, T. I. E. Svidzinski, and M. E. L. Consolaro, “Efficacy of fluconazole and nystatin in the treatment of vaginal Candida species,” Acta Derm Venereol, vol. 92, no. 1, pp. 78-82, 2012, doi: 10.2340/ 00015555-1194.

[14] J. Vráblik, J. Masata, A. Jedlicková, and M. Hájíckova, “Prospective study the prevalence of different Candida strains and their sensitivity to different antimycotic treatment in women with vulvovaginal candidiasis,” Ceska Gynekol, vol. 72, no. 1, pp. 27-32, 2007.

[15] C. T. King, P. D. Rogers, J. D. Cleary, and S. W. Chapman, “Antifungal therapy during
pregnancy,” Clin Infect Dis., vol. 27, no. 5, pp. 1151-1160, 1998, doi: 10.1086/514977.

[16] S. Daniel, R. Rotem, G. Koren, E. Lunenfeld, and A. Levy, “Vaginal antimycotics and the risk for spontaneous abortions,” Am J Obstet Gynecol., vol. 218, no. 6, pp. 601.e1-601.e7, 2018, doi: 10.1016/ J.AJOG.2018. 02.013.

[17] A. G. Prentice and A. Glasmacher, “Making sense of itraconazole pharmacokinetics,” J Antimicrob Chemother, vol. 56, no. 1, 2005, doi: 10.1093/JAC/ DKI220.

[18] C. Charlier, E Hart, A. Lefort et al., “Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?” J Antimicrob Chemother, vol. 57, no. 3, pp. 384-410, 2006, doi: 10.1093/JAC/DKI473.

[19] D. Liu, C. Zhang, L. Wu, L. Zhang, and L. Zhang, “Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta-analysis,” Int J Gynaecol Obstet, vol. 148, no. 1, pp. 6-13, 2020, doi: 10.1002/ IJGO.12993.

DOI: https://doi.org/10.34238/tnu-jst.10930

Refbacks

There are currently no refbacks.



Remember me